Evidence map›Paper›PMID 38481503›Full record

ArticleKidney international reports2024

Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients.

Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, Natasha S Kelkar, Pieter Pannus, Shilpee Sharma, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt and 13 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Nicolas GemanderInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Delphine KemlinInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Stéphanie DepickèreClinical Trial Unit, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Natasha S KelkarDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire, USA.
Pieter PannusInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Shilpee SharmaInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Alexandra WaegemansInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Véronique OlislagersInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Daphnée GeorgesInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Emilie DhondtVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Margarida BragaVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Leo HeyndrickxVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Johan MichielsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Anaïs ThiriardInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Anne LemyDepartment of Nephrology, Marie Curie Hospital, Charleroi, Belgium.
Marylène VandevenneLaboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
Maria E GoossensClinical Trial Unit, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
André MatagneLaboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of Liège, Liège, Belgium.
Isabelle DesombereLaboratory of Immune Response, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Kevin K AriënVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire, USA.
Alain Le MoineInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Arnaud MarchantInstitute for Medical Immunology and Université Libre de Bruxelles Centre for Research in Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
Université Libre de Bruxelles · BEInstituut voor Tropische Geneeskunde · BESciensano (Belgium) · BEDartmouth College · USUniversity of Liège · BEHôpital Civil de Charleroi · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Comorbidities and immunosuppressive therapies are associated with reduced immune responses to primary COVID-19 mRNA vaccination in kidney transplant recipients (KTRs). In healthy individuals, prior SARS-COV-2 infection is associated with increased vaccine responses, a phenotype called hybrid immunity. In this study, we explored the potential influence of immune suppression on hybrid immunity in KTRs. Methods: Eighty-two KTRs, including 59 SARS-CoV-2-naïve (naïve KTRs [N-KTRs]) and 23 SARS-CoV-2-experienced (experienced KTRs [E-KTRs]) patients, were prospectively studied and compared to 106 healthy controls (HCs), including 40 SARS-CoV-2-naïve (N-HCs) and 66 SARS-CoV-2-experienced (E-HCs) subjects. Polyfunctional antibody and T cell responses were measured following 2 doses of BNT162b2 mRNA vaccine. Associations between vaccine responses and clinical characteristics were studied by univariate and multivariate analyses. Results: In naïve KTRs, vaccine responses were markedly lower than in HCs and were correlated with older age, more recent transplantation, kidney retransplantation after graft failure, arterial hypertension, and treatment with mycophenolate mofetil (MMF). In contrast, vaccine responses of E-KTRs were similar to those of HCs and were associated with time between transplantation and vaccination, but not with the other risk factors associated with low vaccine responses in naïve KTRs. Conclusion: In conclusion, hybrid immunity overcomes immune suppression and provides potent humoral and cellular immunity to SARS-CoV-2 in KTRs.

Indexed as

COVID-19hybrid immunitykidney transplantationmRNA vaccinationnonneutralizing antibodiessystems immunology

Identifiers

PMID38481503
PMCPMC10928013
OpenAlexW4389988257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.